



(A) During the 20-week experimentation, muscle performance was evaluated weekly by the *Kondziela's Inverted Screen Test.* Compared to SD, WD consumption reduced muscle functionality, which was rescued by the administration of VM (250 or 500 mg/kg/die). (B) WD vs SD-fed mice showed a reduced (-10%) average myofiber area in gastrocnemius (GC) muscles after staining with H&E, and VM consumption maintained the myofiber areas of WD-fed mice similar to those of SD-fed ones. Myofiber area was evaluated by using the *ImageJ* software. Reported are the percentages of myofiber area changes with respect to SD-fed mice. (C) Real-time PCR analysis of GC muscles revealed that WD activated the ubiquitin-proteasome system (UPS) inducing *Fbxo32* and *Trim63* gene expressions, which were completely counteracted by administration of VM extract. (D) Myosin heavy chain (MyHC)-II and AGEs amounts in GC muscles were evaluated by Western Blotting (WB) analysis and the relative densities were calculated with respect to α -actinin. A reduction in MyHC-II content and accumulation of AGEs were observed in WD-fed mice compared to SD-fed mice, and administration of VM counteracted AGE accumulation, as evaluated by ELISA dosage. Reported are representative images (B,D). Values are means \pm SEM. Statistical analysis was conducted using t-test. *p<0.05, **p<0.01, and ***p<0.001 vs SD-fed mice. *p<0.05, **p<0.01, and ***p<0.001 vs SD-fed mice. *p<0.05, **p<0.01, and ***p<0.001, vs WD-fed mice.

Acknowledgments: CONCLUSIONS WD consumption induced : Increase in body, liver, and adipose tissue weights; VM administration maintained • Liver steatosis; ✓ Physiological weights of liver and eWAT; • Reduction of muscle performance; Fondazione Muscle performance; VERONESI MyHC-II amounts in muscles Ministero dell'Universit a dalla Dirarr (i) 💮 ✓ Myofiber area; Project title: Fighting WESTERN diet-derived AGEs ✓ Low levels of *Fbxo32* and *Trim63* genes; (advanced glycation end products) with natural compounds to mitigate muscle wasting in sarcobesity ✓ Low levels of AGEs in muscles O (WESTERNAGE) #P2022Z4EB5

References: J. Clemente-Suárez et al., Nutrients. 2023; 15:2749; 2. Peppa et al., Nutrients 2021;13:3467; 3. Salazar et al., Int J Environ Res Public Health 2021;18:7236; 4. Salazar et al., Int J Environ Res Public Health. 2021; 18:7236; 5. Chiappalupi et al., J Cachexia Sarcopenia Muscle. 2020; 11:929-946; 6. Vijaykrishnaraj and Wang Biomed Pharmacother. 2021;144:112336; 7. de Souza Gouveia Moreira et al., J Nutr Metab 2024;2024:9590066.